ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Up 114.2% in April

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 250,200 shares, an increase of 114.2% from the March 31st total of 116,800 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 0.2 days. Approximately 1.5% of the shares of the company are short sold.

ASLAN Pharmaceuticals Stock Performance

NASDAQ ASLN traded down $0.03 on Friday, hitting $0.42. The stock had a trading volume of 645,378 shares, compared to its average volume of 869,845. ASLAN Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $4.69. The firm has a 50-day moving average of $0.60 and a 200-day moving average of $0.71.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its earnings results on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. Analysts predict that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ASLN. Piper Sandler reaffirmed an “overweight” rating and issued a $10.00 price objective (down from $15.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of ASLAN Pharmaceuticals in a report on Tuesday, April 23rd.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.